Clinical Trials
34
Active:25
Completed:6
Trial Phases
3 Phases
Phase 1:23
Phase 2:1
Phase 3:5
Drug Approvals
1
EMA:1
Drug Approvals
Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
- Authorization Status
- Authorised
- Approval Date
- Jan 11, 2022
EMA
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)β’ Click on a phase to view related trials
Phase 1
23 (79.3%)Phase 3
5 (17.2%)Phase 2
1 (3.4%)A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Recruiting
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 900
- Registration Number
- NCT05820672
- Locations
- πΊπΈ
Ascendis Investigational Site, Seattle, Washington, United States
πΊπΈAscendis Pharma Investigational Site, Centennial, Colorado, United States
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 500
- Registration Number
- NCT05775523
- Locations
- πΊπΈ
Ascendis Investigational Site, Seattle, Washington, United States
πΊπΈAscendis Pharma Investigational Site, Centennial, Colorado, United States
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Phase 2
Active, not recruiting
- Conditions
- Turner Syndrome
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 48
- Registration Number
- NCT05690386
- Locations
- πΊπΈ
Ascendis Pharma Investigational Site, Seattle, Washington, United States
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Endocrine System DiseasesHormone DeficiencyAdult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 233
- Registration Number
- NCT05171855
- Locations
- π¬π§
Ascendis Pharma Investigational Site, Leeds, United Kingdom
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Hormone DeficiencyEndocrine System DiseasesGrowth Hormone Deficiency
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 264
- Registration Number
- NCT04615273
- Locations
- π¬π§
Ascendis Pharma Investigational Site, Leeds, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found